{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:39:45Z","timestamp":1792629585766,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40487-025-00375-x","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:02:19Z","timestamp":1762992139000},"page":"895-918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Impact of Intravesical Instillations on Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: A Systematic Review"],"prefix":"10.1007","volume":"13","author":[{"given":"Ingolf","family":"Griebsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-7120","authenticated-orcid":false,"given":"Sunil","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Fai","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bottomley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"3","key":"375_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et\u00a0al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"375_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00345-024-04949-8","volume":"42","author":"A W\u00e9ber","year":"2024","unstructured":"W\u00e9ber A, et\u00a0al. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 2024;42(1):237.","journal-title":"World J Urol"},{"issue":"6","key":"375_CR3","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","volume":"205","author":"JT Matulay","year":"2021","unstructured":"Matulay JT, et\u00a0al. Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: implications for clinical trial design. J Urol. 2021;205(6):1612\u201321.","journal-title":"J Urol"},{"issue":"3","key":"375_CR4","doi-asserted-by":"publisher","first-page":"106.e1","DOI":"10.1016\/j.urolonc.2021.10.008","volume":"40","author":"Z Dovey","year":"2022","unstructured":"Dovey Z, et\u00a0al. Bladder cancer (NMIBC) in a population-based cohort from Stockholm County with long-term follow-up; a comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model. Urol Oncol. 2022;40(3):106.e1-106.e10.","journal-title":"Urol Oncol"},{"issue":"2","key":"375_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, et\u00a0al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234\u201341.","journal-title":"Eur Urol"},{"issue":"2","key":"375_CR6","first-page":"43","volume":"22","author":"RS Matulewicz","year":"2020","unstructured":"Matulewicz RS, Steinberg GD. Non-muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies. Rev Urol. 2020;22(2):43\u201351.","journal-title":"Rev Urol"},{"issue":"5","key":"375_CR7","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2022","unstructured":"Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2022;168(5):1964\u201370.","journal-title":"J Urol"},{"issue":"5","key":"375_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41585-022-00578-1","volume":"19","author":"JY Teoh","year":"2022","unstructured":"Teoh JY, et\u00a0al. Recurrence mechanisms of non-muscle-invasive bladder cancer\u2014a clinical perspective. Nat Rev Urol. 2022;19(5):280\u201394.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"375_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/iju.IJU_296_17","volume":"34","author":"KN Rayn","year":"2018","unstructured":"Rayn KN, et\u00a0al. New therapies in nonmuscle invasive bladder cancer treatment. Indian J Urol. 2018;34(1):11\u20139.","journal-title":"Indian J Urol"},{"issue":"4","key":"375_CR10","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1097\/01.ju.0000152314.60154.d7","volume":"173","author":"HW Herr","year":"2005","unstructured":"Herr HW. Legacy of Edwin Beer: fulguration of papillary bladder tumors. J Urol. 2005;173(4):1087\u20139.","journal-title":"J Urol"},{"issue":"4","key":"375_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.euf.2023.06.006","volume":"9","author":"M Kates","year":"2023","unstructured":"Kates M, et\u00a0al. Background and update for ECOG-ACRIN EA8212: a randomized phase 3 trial of intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus intravesical docetaxel and gemcitabine treatment in BCG-na\u00efve high-grade non\u2013muscle-invasive bladder cancer (BRIDGE). Eur Urol Focus. 2023;9(4):561\u20133.","journal-title":"Eur Urol Focus"},{"issue":"5","key":"375_CR12","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, et\u00a0al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update. Eur Urol. 2019;76(5):639\u201357.","journal-title":"Eur Urol"},{"issue":"7","key":"375_CR13","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1007\/s11095-008-9566-7","volume":"25","author":"Z Shen","year":"2008","unstructured":"Shen Z, et\u00a0al. Intravesical treatments of bladder cancer: review. Pharm Res. 2008;25(7):1500\u201310.","journal-title":"Pharm Res"},{"key":"375_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101843","author":"S McNall","year":"2024","unstructured":"McNall S, et\u00a0al. Treatment modalities for non-muscle invasive bladder cancer: an updated review. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16101843.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"375_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-471942","volume":"45","author":"M Filon","year":"2025","unstructured":"Filon M, Schmidt B. New treatment options for non-muscle-invasive bladder cancer. Am Soc Clin Oncol Educ Book. 2025;45(2): e471942.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"375_CR16","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.21037\/tau-20-1333","volume":"10","author":"A Nayak","year":"2021","unstructured":"Nayak A, Cresswell J, Mariappan P. Quality of life in patients undergoing surveillance for non-muscle invasive bladder cancer-a systematic review. Transl Androl Urol. 2021;10(6):2737\u201349.","journal-title":"Transl Androl Urol"},{"issue":"3","key":"375_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1179\/1973947813Y.0000000126","volume":"26","author":"L Wei","year":"2014","unstructured":"Wei L, et\u00a0al. The quality of life in patients during intravesical treatment and correlation with local symptoms. J Chemother. 2014;26(3):165\u20138.","journal-title":"J Chemother"},{"issue":"5","key":"375_CR18","first-page":"9480","volume":"25","author":"S Siracusano","year":"2018","unstructured":"Siracusano S, et\u00a0al. Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer. Can J Urol. 2018;25(5):9480\u20135.","journal-title":"Can J Urol"},{"issue":"1","key":"375_CR19","doi-asserted-by":"publisher","first-page":"19.e7","DOI":"10.1016\/j.urolonc.2014.09.012","volume":"33","author":"S Schmidt","year":"2015","unstructured":"Schmidt S, et\u00a0al. Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study. Urol Oncol. 2015;33(1):19.e7-19.e15.","journal-title":"Urol Oncol"},{"key":"375_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph191710825","author":"JW Yuen","year":"2022","unstructured":"Yuen JW, et\u00a0al. Impact of effective intravesical therapies on quality of life in patients with non-muscle invasive bladder cancer: a systematic review. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/ijerph191710825.","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"375_CR21","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","volume":"176","author":"M Colombel","year":"2006","unstructured":"Colombel M, et\u00a0al. The effect of ofloxacin on Bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176(3):935\u20139.","journal-title":"J Urol"},{"issue":"5","key":"375_CR22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1464-410X.2009.08469.x","volume":"104","author":"R Damiano","year":"2009","unstructured":"Damiano R, et\u00a0al. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu\u00e9rin-induced toxicity? BJU Int. 2009;104(5):633\u20139.","journal-title":"BJU Int"},{"issue":"3","key":"375_CR23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, et\u00a0al. Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462\u201372.","journal-title":"Eur Urol"},{"key":"375_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03738-z","author":"ND Shore","year":"2025","unstructured":"Shore ND, et\u00a0al. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03738-z.","journal-title":"Nat Med"},{"issue":"4","key":"375_CR25","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrurol.2017.16","volume":"14","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, et\u00a0al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol. 2017;14(4):244\u201355.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"375_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/BLC-180191","volume":"4","author":"JJ de Jong","year":"2018","unstructured":"de Jong JJ, et\u00a0al. Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients. Bladder Cancer. 2018;4(4):395\u2013401.","journal-title":"Bladder Cancer"},{"issue":"4","key":"375_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM, et\u00a0al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol. 2024;211(4):533\u20138.","journal-title":"J Urol"},{"key":"375_CR28","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"J Chandler","year":"2019","unstructured":"Chandler J. Cochrane handbook for systematic reviews of interventions. Hoboken: Wiley; 2019."},{"key":"375_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, et\u00a0al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"key":"375_CR30","unstructured":"Wells GA, et\u00a0al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000."},{"issue":"2","key":"375_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/ijun.12191","volume":"13","author":"J Alcorn","year":"2019","unstructured":"Alcorn J, Burton R, Topping A. Patterns of patient withdrawal from BCG treatment for bladder cancer: a retrospective time interval analysis. Int J Urol Nurs. 2019;13(2):63\u201374.","journal-title":"Int J Urol Nurs"},{"issue":"3","key":"375_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/ijun.12236","volume":"14","author":"J Alcorn","year":"2020","unstructured":"Alcorn J, Burton R, Topping A. Withdrawing from treatment for bladder cancer: patient experiences of BCG installations. Int J Urol Nurs. 2020;14(3):106\u201314.","journal-title":"Int J Urol Nurs"},{"issue":"10","key":"375_CR33","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.3390\/cancers16101936","volume":"16","author":"L Blichert-Refsgaard","year":"2024","unstructured":"Blichert-Refsgaard L, et\u00a0al. Use of bladder-related medication in non-muscle invasive bladder cancer patients. Cancers (Basel). 2024;16(10):1936.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"375_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3233\/BLC-170138","volume":"4","author":"T Garg","year":"2018","unstructured":"Garg T, et\u00a0al. Defining priorities to improve patient experience in non-muscle invasive bladder cancer. Bladder Cancer. 2018;4(1):121\u20138.","journal-title":"Bladder Cancer"},{"issue":"3","key":"375_CR35","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.juro.2013.03.097","volume":"190","author":"P Gontero","year":"2013","unstructured":"Gontero P, et\u00a0al. The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol. 2013;190(3):857\u201362.","journal-title":"J Urol"},{"issue":"9","key":"375_CR36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1442-2042.2010.02584.x","volume":"17","author":"H Koga","year":"2010","unstructured":"Koga H, et\u00a0al. Maintenance intravesical Bacillus Calmette-Gu\u00e9rin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol. 2010;17(9):759\u201366.","journal-title":"Int J Urol"},{"key":"375_CR37","doi-asserted-by":"crossref","unstructured":"Kopenhafer L, et\u00a0al. Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: insights from qualitative interviews and a cross-sectional survey. In: Urologic oncology: seminars and original investigations. Amsterdam: Elsevier; 2024.","DOI":"10.1016\/j.urolonc.2024.01.013"},{"key":"375_CR38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.urology.2021.04.062","volume":"156","author":"JM Kuperus","year":"2021","unstructured":"Kuperus JM, et\u00a0al. Comparison of side effects and tolerability between intravesical Bacillus Calmette-Guerin, reduced-dose BCG and gemcitabine for non-muscle invasive bladder cancer. Urology. 2021;156:191\u20138.","journal-title":"Urology"},{"issue":"1","key":"375_CR39","first-page":"887","volume":"30","author":"M Miyake","year":"2022","unstructured":"Miyake M, et\u00a0al. Intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: functional outcome assessment based on a questionnaire survey and actigraphy. Support Care Cancer. 2022;30(1):887\u201395.","journal-title":"Support Care Cancer"},{"key":"375_CR40","doi-asserted-by":"crossref","unstructured":"Myers A, et\u00a0al. Patient reported treatment burden and attitudes towards in-home intravesical therapy among patients with bladder cancer. In: Urologic oncology: seminars and original investigations. Amsterdam: Elsevier; 2024.","DOI":"10.1016\/j.urolonc.2023.09.006"},{"issue":"1","key":"375_CR41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000430501","volume":"96","author":"V Serretta","year":"2016","unstructured":"Serretta V, et\u00a0al. Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials? Urol Int. 2016;96(1):20\u20134.","journal-title":"Urol Int"},{"issue":"4","key":"375_CR42","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/bju.15567","volume":"129","author":"JD Subiela","year":"2022","unstructured":"Subiela JD, et\u00a0al. Contemporary outcomes of bladder carcinoma in situ treated with an adequate Bacille Calmette-Gu\u00e9rin immunotherapy. BJU Int. 2022;129(4):542\u201350.","journal-title":"BJU Int"},{"key":"375_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.euros.2023.08.004","volume":"56","author":"CG van Straten","year":"2023","unstructured":"van Straten CG, et\u00a0al. Quality of life in patients with high-grade non-muscle-invasive bladder cancer undergoing standard versus reduced frequency of Bacillus Calmette-Gu\u00e9rin instillations: the EAU-RF NIMBUS trial. Eur Urol Open Sci. 2023;56:15\u201324.","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"375_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3233\/BLC-200397","volume":"7","author":"AX Vo","year":"2021","unstructured":"Vo AX, et\u00a0al. Evaluating patient-defined priorities for female patients with bladder cancer. Bladder Cancer. 2021;7(1):53\u201360.","journal-title":"Bladder Cancer"},{"issue":"11","key":"375_CR45","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036871","volume":"103","author":"W Wang","year":"2024","unstructured":"Wang W, Chen Y, Gu J. Effectiveness of integrated nursing interventions in enhancing patient outcomes during postoperative intravesical instillation for non-muscle invasive bladder cancer: a comparative study. Medicine (Baltimore). 2024;103(11): e36871.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"375_CR46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/ijun.12246","volume":"15","author":"SM Wildeman","year":"2021","unstructured":"Wildeman SM, van Golde C, Nooter RI. Psychosocial issues during the treatment of non-muscle invasive bladder cancer. Int J Urol Nurs. 2021;15(1):12\u20139.","journal-title":"Int J Urol Nurs"},{"key":"375_CR47","unstructured":"Gontero P, et\u00a0al. EAU guidelines. In: Edn. presented at the EAU annual congress, Milan. 2023."},{"key":"375_CR48","unstructured":"NCCN. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) bladder cancer version 4.2024\u2014May 9, 2024. 2024 [cited 2025 February 28]. https:\/\/www.nccn.org\/patientresources\/patient-resources\/guidelines-for-patients\/guidelines-for-patients-details?patientGuidelineId=4."},{"issue":"5","key":"375_CR49","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"MO Grimm","year":"2020","unstructured":"Grimm MO, et\u00a0al. Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation randomised phase III clinical trial \u201cNIMBUS.\u201d Eur Urol. 2020;78(5):690\u20138.","journal-title":"Eur Urol"},{"key":"375_CR50","unstructured":"Chou R, et\u00a0al. AHRQ comparative effectiveness reviews. In: Emerging approaches to diagnosis and treatment of non-muscle-invasive bladder cancer. Rockville: Agency for Healthcare Research and Quality; 2015."},{"issue":"6","key":"375_CR51","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","volume":"25","author":"A Necchi","year":"2024","unstructured":"Necchi A, et\u00a0al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024;25(6):720\u201330.","journal-title":"Lancet Oncol"},{"issue":"6","key":"375_CR52","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","volume":"84","author":"PC Black","year":"2023","unstructured":"Black PC, et\u00a0al. Phase 2 trial of atezolizumab in Bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605. Eur Urol. 2023;84(6):536\u201344.","journal-title":"Eur Urol"},{"issue":"4","key":"375_CR53","first-page":"188","volume":"9","author":"AL Shields","year":"2016","unstructured":"Shields AL, et\u00a0al. Patient-reported outcomes in oncology drug labeling in the united states: a framework for navigating early challenges. Am Health Drug Benefits. 2016;9(4):188\u201397.","journal-title":"Am Health Drug Benefits"},{"key":"375_CR54","volume-title":"Core patient-reported outcomes in cancer clinical trials: guidance for industry","author":"Food and Drug Administration","year":"2021","unstructured":"Food and Drug Administration. Core patient-reported outcomes in cancer clinical trials: guidance for industry. Silver Spring: US Department of Health and Human Services; 2021.\u00a0https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/core-patient-reported-outcomes-cancer-clinical-trials"},{"key":"375_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-024-01558-7","author":"K Schubach","year":"2024","unstructured":"Schubach K, et\u00a0al. Identifying the supportive care needs of people affected by non-muscle invasive bladder cancer: an integrative systematic review. J Cancer Surviv. 2024. https:\/\/doi.org\/10.1007\/s11764-024-01558-7.","journal-title":"J Cancer Surviv"},{"issue":"1","key":"375_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian SA, et\u00a0al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021;22(1):107\u201317.\u00a0https:\/\/doi.org\/10.1016\/S1470-2045(20)30540-4","journal-title":"Lancet Oncol"},{"issue":"2","key":"375_CR57","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3233\/BLC-230083","volume":"10","author":"AR Steinmetz","year":"2024","unstructured":"Steinmetz AR, et\u00a0al. The evolution of nadofaragene firadenovec: a review and the path forward. Bladder Cancer. 2024;10(2):105\u201312.\u00a0https:\/\/doi.org\/10.3233\/BLC-230083\u00a0","journal-title":"Bladder Cancer"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00375-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00375-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00375-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:03:10Z","timestamp":1764090190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00375-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00375-x","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yair Lotan has served as a consultant for Photocure, AstraZeneca, Merck, Fergene, Nucleix, Ambu, Seattle Genetics, Virtuoso Surgical, Stimit, Urogen, Vessi Medical, CAPs Medical, Nonagen, Aura Biosciences, Inc., Convergent Genomics, Pacific Edge, Pfizer, Phinomics Inc., CG Oncology, UroViu, Promis Diagnostics, Valar Labs, UroEssentials, NRx Pharmaceuticals, Vesica Health, Janssen, ImmunityBio, Trigone Pharma, and Relmada. Andrew Bottomley is the owner of Bottomley Consulting Group and has been funded for this specific work from Ferring Pharmaceutical company. He also has several grants and other income sources for work involving a number of pharmaceutical companies.\u00a0Ingolf Griebsch is an employee of Ferring Pharmaceutical company which funded this work. Sunil Shrestha, and Chi-Fai Ng have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}